Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2020 Feb 18

PMID 32064265

Citations 6

Authors

Jack S Cornish

Elisa Wirthgen

Jan Dabritz

Affiliations

Soon will be listed here.

Abstract

The complex nature of inflammatory bowel disease (IBD) often results in treatment failure for many patients. With some patients cycling through multiple therapies before achieving a sustained period of remission, the ability to predict a patient's response to therapeutics could decrease the time from active disease to clinical remission and mucosal healing. The prospect of such individualized treatment of IBD would be aided by accurate biomarkers, both fecal and serological, which have to date shown value as indicators of IBD activity. Here we review the utility of generic biomarkers for inflammation or mucosal healing, such as calprotectin, C-reactive protein (CRP), and fecal hemoglobin (fHb) as predictors of response to treatment of IBD. We further provide a deeper insight into the utility of monitoring the thiopurine treatment by thiopurine metabolites or alternative hematologic parameters. In light of multiple recent publications of biomarkers and biological therapy, our focus in this review is predicting response to thiopurine treatment only, that is, Azathioprine and 6-Mercaptopurine.

Citing Articles

Assessment of the Utility of Selected Inflammatory Markers in Correlation with Magnetic Resonance Enterography (MRE) Findings in the Diagnosis of Crohn's Disease.

Lorenc-Gora J, Waniczek D, Czuba Z, Kryj M, Lorenc Z, Muc-Wierzgon M Biomolecules. 2025; 15(1).

PMID: 39858510 PMC: 11763748. DOI: 10.3390/biom15010116.

White Blood Cell Counts and Future Relapse in Ulcerative Colitis under Low-Dose Thiopurine Treatment in Real-World Practice: A 3-Year Japanese Multi-Center Retrospective Cohort Study.

Kiyohara H, Yamazaki H, Moriya K, Akimoto N, Kawai S, Takenaka K Inflamm Intest Dis. 2024; 9(1):1-10.

PMID: 38298887 PMC: 10830139. DOI: 10.1159/000535889.

Identifying predictors of clinical outcomes using the projection-predictive feature selection-a proof of concept on the example of Crohn's disease.

Wirthgen E, Weber F, Kubickova-Weber L, Schiller B, Schiller S, Radke M Front Pediatr. 2023; 11:1170563.

PMID: 37576142 PMC: 10420065. DOI: 10.3389/fped.2023.1170563.

Effects of Pine Pollen Polysaccharides and Sulfated Polysaccharides on Ulcerative Colitis and Gut Flora in Mice.

Wang Y, Song X, Wang Z, Li Z, Geng Y Polymers (Basel). 2023; 15(6).

PMID: 36987195 PMC: 10058757. DOI: 10.3390/polym15061414.

Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease.

Zakerska-Banaszak O, Lykowska-Szuber L, Walczak M, Zuraszek J, Zielinska A, Skrzypczak-Zielinska M Toxics. 2022; 10(4).

PMID: 35448412 PMC: 9026123. DOI: 10.3390/toxics10040151.

References

Thomas Jr C, Lowry P, Franklin C, Weaver A, Myhre G, Mays D . Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis. 2003; 9(4):237-45. DOI: 10.1097/00054725-200307000-00004. View

Roseth A, Schmidt P, Fagerhol M . Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999; 34(1):50-4. DOI: 10.1080/00365529950172835. View

Schroeder K, Tremaine W, Ilstrup D . Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317(26):1625-9. DOI: 10.1056/NEJM198712243172603. View

Treton X, Bouhnik Y, Mary J, Colombel J, Duclos B, Soule J . Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol. 2008; 7(1):80-5. DOI: 10.1016/j.cgh.2008.08.028. View

Bokkerink J, De Abreu R, Bakker M, Hulscher T, van Baal J, SCHRETLEN E . Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages. Biochem Pharmacol. 1988; 37(12):2329-38. DOI: 10.1016/0006-2952(88)90359-0. View

Sparrow M, Hande S, Friedman S, Lim W, Reddy S, Cao D . Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005; 22(5):441-6. DOI: 10.1111/j.1365-2036.2005.02583.x. View

Cuffari C . A Physician's Guide to Azathioprine Metabolite Testing. Gastroenterol Hepatol (N Y). 2017; 2(1):58-63. PMC: 5307263. View

Gonzalez-Lama Y, Bermejo F, Lopez-Sanroman A, Garcia-Sanchez V, Esteve M, Cabriada J . Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther. 2011; 34(5):544-54. DOI: 10.1111/j.1365-2036.2011.04756.x. View

Naviglio S, Giuffrida P, Stocco G, Lenti M, Ventura A, Corazza G . How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2018; 12(8):797-810. DOI: 10.1080/17474124.2018.1494573. View

10.

Mowat C, Digby J, Strachan J, Wilson R, Carey F, Fraser C . Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms. Gut. 2015; 65(9):1463-9. PMC: 5036251. DOI: 10.1136/gutjnl-2015-309579. View

11.

Sands B . Biomarkers of Inflammation in Inflammatory Bowel Disease. Gastroenterology. 2015; 149(5):1275-1285.e2. DOI: 10.1053/j.gastro.2015.07.003. View

12.

Mooiweer E, Fidder H, Siersema P, Laheij R, Oldenburg B . Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation. Inflamm Bowel Dis. 2013; 20(2):307-14. DOI: 10.1097/01.MIB.0000438428.30800.a6. View

13.

Osterman M, Kundu R, Lichtenstein G, Lewis J . Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006; 130(4):1047-53. DOI: 10.1053/j.gastro.2006.01.046. View

14.

McDonald P, Digby J, Innes C, Strachan J, Carey F, Steele R . Low faecal haemoglobin concentration potentially rules out significant colorectal disease. Colorectal Dis. 2012; 15(3):e151-9. DOI: 10.1111/codi.12087. View

15.

Smith M, Blaker P, Marinaki A, Anderson S, Irving P, Sanderson J . Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis. 2012; 6(9):905-12. DOI: 10.1016/j.crohns.2012.02.007. View

16.

Mosli M, Sandborn W, Kim R, Khanna R, Al-Judaibi B, Feagan B . Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014; 109(7):994-1004. DOI: 10.1038/ajg.2014.110. View

17.

Jurgens M, Mahachie John J, Cleynen I, Schnitzler F, Fidder H, van Moerkercke W . Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011; 9(5):421-7.e1. DOI: 10.1016/j.cgh.2011.02.008. View

18.

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

19.

Khanna R, Narula N, Feagan B . The Role of Biomarkers in Clinical Trials of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018; 24(8):1619-1623. DOI: 10.1093/ibd/izy195. View

20.

Magro F, Rodrigues-Pinto E, Santos-Antunes J, Vilas-Boas F, Lopes S, Nunes A . High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment. J Crohns Colitis. 2013; 8(2):129-36. DOI: 10.1016/j.crohns.2013.07.005. View